End Stage Renal Disease (ESRD) Clinical Trial
Official title:
A Prospective Multicenter Investigation to Evaluate the Safety of the Bayston Antimicrobial Peritoneal Dialysis Catheter in ESRD Patients
The study was designed to establish the safety of the Bayston Antimicrobial PD catheter that is impregnated with a "cocktail" of three well known anti-microbials
The objective of this clinical investigation is to establish the safety of the Bayston Antimicrobial Peritoneal Dialysis Catheter in ESRD patients initiating CAPD. The Bayston catheter is not expected to cause any safety related complications or reactions other than those described for not-impregnated peritoneal dialysis catheters. Thus the objective of this clinical investigation is to evaluate whether the Bayston catheter causes any unanticipated serious adverse device effects (USADE). The primary hypothesis for this study is that the Bayston Antimicrobial Peritoneal Dialysis Catheter is a safe catheter for peritoneal dialysis. No claims regarding efficacy will be verified during this clinical investigation. This is a prospective, non-randomized, single-arm, multi-center study involving patients suffering from end stage renal disease who are eligible for treatment with peritoneal dialysis. Forty-three (43) patients will be enrolled who will be followed up to 6 months after implantation of the Bayston Antimicrobial Peritoneal Dialysis Catheter. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05908084 -
To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
|
Phase 3 | |
Active, not recruiting |
NCT05309109 -
Effect of Medium Cut-Off Hemodialysis on Protein Energy Wasting: The EMCOPEW Study
|
N/A | |
Not yet recruiting |
NCT04086212 -
Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine
|
Phase 2 | |
Completed |
NCT01783626 -
Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)
|
N/A | |
Active, not recruiting |
NCT01693263 -
Outcome of BCF Access in Hemodialysis Patients
|
||
Completed |
NCT01219959 -
Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
|
Phase 3 | |
Completed |
NCT02278341 -
Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
|
Phase 3 | |
Completed |
NCT02593149 -
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
|
N/A | |
Completed |
NCT04912050 -
EXtension of Tablo TrEatmeNt Duration Registry
|
||
Recruiting |
NCT02745340 -
Substitution of Acetate by Citrate in the Bicarbonate Based Hemodialysis
|
N/A | |
Completed |
NCT02733328 -
Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
|
||
Completed |
NCT04292184 -
Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation
|
Phase 1 | |
Completed |
NCT02795286 -
Automated Setting of Individualized Sodium Technology
|
N/A | |
Active, not recruiting |
NCT02808208 -
Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
|
Phase 1/Phase 2 | |
Completed |
NCT00559767 -
Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium
|
N/A | |
Completed |
NCT02433210 -
A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
|
N/A | |
Completed |
NCT01594424 -
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT05610683 -
Comparison of the Removal of Uremic Toxins With Medium Cut-off and Super High-flux Vitamin E-coated Dialyzers
|
N/A | |
Completed |
NCT03249532 -
Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis
|
N/A | |
Completed |
NCT02467530 -
Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis
|
N/A |